$3.89
-0.02 (-0.38%)
Open$3.93
Previous Close$3.91
Day High$4.19
Day Low$3.86
52W High$7.20
52W Low$3.75
Volume—
Avg Volume45.9K
Market Cap8.21M
P/E Ratio—
EPS$-16.34
SectorBiotechnology
Analyst Ratings
Buy
10 analysts
Price Target
+577.9% upside
Current
$3.89
$3.89
Target
$26.37
$26.37
$21.16
$26.37 avg
$30.50
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 7.91M | 7.17M | 3.98M |
| Net Income | -34,297,852 | -27,977,945 | 267.7K |
| Profit Margin | -433.7% | -412.1% | 6.7% |
| EBITDA | -35,783,800 | -30,811,755 | 477.9K |
| Free Cash Flow | — | — | 225.1K |
| Rev Growth | +10.3% | +10.3% | +11.2% |
| Debt/Equity | — | — | 0.39 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.53 | -1.09% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $361.16 | +0.17% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.13 | -0.16% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $494.74 | -0.98% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $628.06 | -0.59% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $297.43 | +1.33% | 69.3 | 39.97B |